Sanofi
A global biopharmaceutical company that discovers, develops, and markets medicines and vaccines.
SAN | PA
Overview
Corporate Details
- ISIN(s):
- FR0000120578 (+39 more)
- LEI:
- 549300E9PC51EN656011
- Country:
- France
- Address:
- 46 AVENUE DE LA GRANDE ARMEE, 75017 PARIS
- Sector:
- Manufacturing
Description
Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-05-10 08:00 |
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to …
|
English | 183.5 KB | ||
| 2024-05-02 21:52 |
6-K
|
English | 59.4 KB | ||
| 2024-05-02 07:00 |
Communiqué de presse : Des données de vie réelle concernant Beyfortus publiées …
|
French | 240.6 KB | ||
| 2024-05-02 07:00 |
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% …
|
English | 235.3 KB | ||
| 2024-04-30 18:00 |
Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2024
|
French | 144.2 KB | ||
| 2024-04-30 18:00 |
Press Release: Annual General Meeting of April 30, 2024
|
English | 140.0 KB | ||
| 2024-04-25 16:49 |
6-K
|
English | 273.9 KB | ||
| 2024-04-25 07:30 |
Communiqué de presse : Sanofi réitère ses objectifs financiers pour 2024, après…
|
French | 446.0 KB | ||
| 2024-04-25 07:30 |
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins …
|
English | 410.4 KB | ||
| 2024-04-24 15:36 | English | 57.5 KB | |||
| 2024-04-24 12:51 | English | 8.0 KB | |||
| 2024-04-23 07:00 |
Communiqué de presse : L’étude de phase III LUNA 3 du rilzabrutinib pour le tra…
|
French | 186.9 KB | ||
| 2024-04-23 07:00 |
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immun…
|
English | 191.9 KB | ||
| 2024-04-17 07:00 |
Communiqué de presse : De nouveaux résultats de phase II à 48 semaines relatifs…
|
French | 212.7 KB | ||
| 2024-04-17 07:00 |
Press Release: New 48-week frexalimab phase 2 data support potential for high s…
|
English | 205.6 KB |
Automate Your Workflow. Get a real-time feed of all Sanofi filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Sanofi
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Sanofi via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-02 | N/A | Other | Buy | 71,423 | N/A |
| 2024-04-26 | N/A | Other | Buy | 1,000 | 91,380.00 EUR |
| 2023-06-09 | N/A | Other | Buy | 9 | 856.04 EUR |
| 2023-05-02 | N/A | Other | Buy | 65,205 | 6,364,008.00 EUR |
| 2023-05-02 | N/A | Other | Buy | 500 | 48,835.00 EUR |
Peer Companies
